Phase II study of dolastatin-10 in patients with advanced non-small-cell lung cancer.
Krug
L M
LM
Department of Medicine, Memorial Sloan-Kettering Cancer Center, Weill Medical College of Cornell University, New York, New York 10021, USA.
Miller
V A
VA
Kalemkerian
G P
GP
Kraut
M J
MJ
Ng
K K
KK
Heelan
R T
RT
Pizzo
B A
BA
Perez
W
W
McClean
N
N
Kris
M G
MG
D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002289:Carcinoma, Non-Small-Cell Lung / Q000175:diagnosis / Q000188:drug therapy*; D047630:Depsipeptides; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007262:Infusions, Intravenous; D008175:Lung Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D009842:Oligopeptides / Q000008:administration & dosage* / Q000009:adverse effects; D012720:Severity of Illness Index; D015996:Survival Rate; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D047630:Depsipeptides; D009842:Oligopeptides; C064570:dolastatin 10